Sign In

Salvatore G Viscomi, MD

Physician Entrepreneur: Building a next generation population screening, monitoring and care management platform for Chronic Kidney Disease leveraging point-of-care testing and AI-driven software.

Salvatore Giovanni Viscomi, MD is a self-directed and driven health care professional with extensive experience in commercial strategy, R&D, therapy product development, innovation, medical imaging, biomarkers, and asset valuation.

He is known for his innovative thinking, strong background in life sciences and bioinformatics, and acute business acumen, with a demonstrated track record of success in navigating complex, HIPAA-regulated environments.

Salvatore has a knack for translating intricate medical concepts into simple product ideas and excels at leading cross-functional teams through challenging projects. He has managed multi-million dollar product portfolios, advised top-tier executives, and authored numerous peer-reviewed articles and medical text chapters.

His expertise spans a wide range of areas including digital health, genetic testing, biomarkers, medical devices, radiology, oncology, infectious diseases, genetics, medical education, cardiovascular health, neuroscience, and more.

Salvatore's educational background includes a Doctor of Medicine from Rutgers University, an executive education in organizational leadership from Harvard Business School, and a residency at Harvard Medical School.

He has held various leadership positions in prestigious organizations such as Chief Executive Officer at Carna Health, Chief Strategy Advisor at Dama Health, and as a member of the Board of Directors at Make-A-Wish® Massachusetts and Rhode Island.

Salvatore's contributions extend to academia, having been an Assistant Professor in Radiology at the University of Massachusetts Medical School and a Faculty member at Harvard Medical School.

Highlights

Aug 15 · linkedin

Excited to share compelling results from our chronic kidney disease screening pilot in Cameroon. Fantastic work by RONALD GOBINA, the principal investor of the study and Nova Biomedical our device partner for this program.

The next phase of the program in Cameroon will include a wider population health screening program for up to 50,000 people. Carna Health also has plans to expand global CKD screening over the next 12-24 months in additional African markets, the Philippines, the Caribbean region, Europe and USA.

May 9 · linkedin

Excited to share Carna Health’s first press release. I am so proud of the world class team that is joining me on our mission to transform chronic kidney disease screening and monitoring while addressing global disparities in care. Thank you to our partner Nova Biomedical for sharing the same commitment and vision. #ckd #digitalhealth #populationhealth

Salvatore G Viscomi, MD
Add to my network

Location

New York, New York, United States